Literature DB >> 32038913

Can liquid biopsy-guided EGFR-targeted therapy be a surrogate for the tissue-based standard approach?

In-Jae Oh1,2.   

Abstract

Entities:  

Year:  2019        PMID： 32038913      PMCID： PMC6987342          DOI： 10.21037/tlcr.2019.06.03

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  21 in total

1.  Detection of epidermal growth factor receptor mutations in circulating tumor DNA: reviewing BENEFIT clinical trial.

Authors:  Umberto Malapelle; Luis E Raez; Maria Jose Serrano; Christian Rolfo
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

Review 2.  Liquid biopsy: monitoring cancer-genetics in the blood.

Authors:  Emily Crowley; Federica Di Nicolantonio; Fotios Loupakis; Alberto Bardelli
Journal:  Nat Rev Clin Oncol       Date:  2013-07-09       Impact factor: 66.675

Review 3.  Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.

Authors:  Jason D Merker; Geoffrey R Oxnard; Carolyn Compton; Maximilian Diehn; Patricia Hurley; Alexander J Lazar; Neal Lindeman; Christina M Lockwood; Alex J Rai; Richard L Schilsky; Apostolia M Tsimberidou; Patricia Vasalos; Brooke L Billman; Thomas K Oliver; Suanna S Bruinooge; Daniel F Hayes; Nicholas C Turner
Journal:  J Clin Oncol       Date:  2018-03-05       Impact factor: 44.544

Review 4.  Epidermal growth factor receptor mutations in lung cancer.

Authors:  Sreenath V Sharma; Daphne W Bell; Jeffrey Settleman; Daniel A Haber
Journal:  Nat Rev Cancer       Date:  2007-03       Impact factor: 60.716

Review 5.  Liquid biopsies come of age: towards implementation of circulating tumour DNA.

Authors:  Jonathan C M Wan; Charles Massie; Javier Garcia-Corbacho; Florent Mouliere; James D Brenton; Carlos Caldas; Simon Pacey; Richard Baird; Nitzan Rosenfeld
Journal:  Nat Rev Cancer       Date:  2017-02-24       Impact factor: 60.716

6.  Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial.

Authors:  Zhijie Wang; Ying Cheng; Tongtong An; Hongjun Gao; Kai Wang; Qing Zhou; Yanping Hu; Yong Song; Cuimin Ding; Feng Peng; Li Liang; Yi Hu; Cheng Huang; Caicun Zhou; Yuankai Shi; Li Zhang; Xin Ye; Meizhuo Zhang; Shaokun Chuai; Guanshan Zhu; Jin Hu; Yi-Long Wu; Jie Wang
Journal:  Lancet Respir Med       Date:  2018-07-17       Impact factor: 30.700

7.  Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).

Authors:  C Zhou; Y L Wu; G Chen; J Feng; X-Q Liu; C Wang; S Zhang; J Wang; S Zhou; S Ren; S Lu; L Zhang; C Hu; C Hu; Y Luo; L Chen; M Ye; J Huang; X Zhi; Y Zhang; Q Xiu; J Ma; L Zhang; C You
Journal:  Ann Oncol       Date:  2015-07-03       Impact factor: 32.976

8.  Circulating tumor DNA analysis in patients with EGFR mutant lung cancer.

Authors:  Shigeki Nanjo; Trever G Bivona
Journal:  J Thorac Dis       Date:  2018-11       Impact factor: 3.005

Review 9.  ctDNA and CTCs in Liquid Biopsy - Current Status and Where We Need to Progress.

Authors:  Martin H D Neumann; Sebastian Bender; Thomas Krahn; Thomas Schlange
Journal:  Comput Struct Biotechnol J       Date:  2018-06-01       Impact factor: 7.271

10.  Feasibility of re-biopsy and EGFR mutation analysis in patients with non-small cell lung cancer.

Authors:  Tae-Ok Kim; In-Jae Oh; Bo Gun Kho; Ha Young Park; Jin Sun Chang; Cheol-Kyu Park; Hong-Joon Shin; Jung-Hwan Lim; Yong-Soo Kwon; Yu-Il Kim; Sung-Chul Lim; Young-Chul Kim; Yoo-Duk Choi
Journal:  Thorac Cancer       Date:  2018-05-14       Impact factor: 3.500
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.